Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Fineline Cube Dec 23, 2025
Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Medical Device

Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review

Fineline Cube Sep 13, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4

Fineline Cube Sep 13, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...

Company Drug

Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment

Fineline Cube Sep 13, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development

Fineline Cube Sep 13, 2023

China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...

Company Deals

Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO

Fineline Cube Sep 13, 2023

Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...

Company Deals

Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091

Fineline Cube Sep 13, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...

Company Medical Device

Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring

Fineline Cube Sep 13, 2023

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...

Company Drug

Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China

Fineline Cube Sep 12, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...

Company Drug

HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China

Fineline Cube Sep 12, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...

Company Drug

Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA

Fineline Cube Sep 12, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Company Deals

Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China

Fineline Cube Sep 12, 2023

China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB...

Company Drug

FDA Extends Pfizer’s Comirnaty Vaccine Indication for Omicron XBB.1.5 Variant

Fineline Cube Sep 12, 2023

The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) an indication extension...

Company Drug

Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial

Fineline Cube Sep 12, 2023

Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...

Company Drug

Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial

Fineline Cube Sep 12, 2023

Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...

Company Deals

Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology

Fineline Cube Sep 12, 2023

Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly...

Company Deals

Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17

Fineline Cube Sep 12, 2023

The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...

Policy / Regulatory

China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances

Fineline Cube Sep 12, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Drug

Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials

Fineline Cube Sep 12, 2023

China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...

Company Deals

Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds

Fineline Cube Sep 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA: 688131) has...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study

Fineline Cube Sep 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 409 410 411 … 601

Recent updates

  • NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display
  • Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
  • Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display

Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.